ORKAMBI® (lumacaftor; ivacaftor)

LENGTH OF AUTHORIZATION: 6 months

INITIAL REVIEW CRITERIA:
- Patient must be ≥ 2 years old; AND
- Patient must have a confirmed diagnosis of Cystic Fibrosis; AND
- Patient must be determined to be homozygous for the F508del mutation in the CFTR gene as confirmed by an FDA-approved CF mutation test; AND
- Patients ages 2 to <18 must have undergone a baseline ophthalmic examination to monitor for lens opacities/cataracts.
- Baseline serum transaminases and bilirubin are required prior to therapy and every 3 months for the first year.
- Please note clinical experience in patients with percent predicted FEV₁ (ppFEV₁) <40 is limited, and additional monitoring of these patients is recommended during initiation of therapy.

CONTINUATION OF THERAPY
- Patient has stable or improved FEV₁.
- Clinical notes document improvement in patient symptoms.
- Serum transaminases and bilirubin levels every 3 months for the first year of treatment and annually thereafter.
- Patients ages 2 to <18 should have a follow up ophthalmic examination at least annually.

DOSING & ADMINISTRATION:
- Patients 12 years and older: 2 tablets (each containing lumacaftor 200 mg and ivacaftor 125 mg) by mouth every 12 hours with a fat-containing food (such as whole milk, cheese, eggs, nuts, etc).
- Patients 6-11 years old: 2 tablets (each containing lumacaftor 100 mg and ivacaftor 125 mg) by mouth every 12 hours with a fat-containing food.
- Patients 2-5 years old weighing more than 14 kg: 1 packet (each containing lumacaftor 150 mg and ivacaftor 188 mg packet of granules) every 12 hours with fat-containing food.
- Patients 2-5 years old weighing less than 14 kg: 1 packet (each containing lumacaftor 100 mg and ivacaftor 125 mg packet of granules) every 12 hours with fat-containing food.